IO Biotech (IOBT) Stock Forecast & Price Target

IO Biotech Inc has demonstrated promising results for Cylembio in combination with pembrolizumab (pembro), showing enhanced immune responses that underscore the product's immune-modulating mechanism of action, thereby potentially improving treatment outcomes in oncology. The projected revenue from modest royalty streams is expected to increase significantly, indicating a positive growth trajectory with estimates rising from $6.1 million in fiscal year 2027 to $88.3 million by 2032, suggesting a strong market presence post-launch in the European Union for advanced melanoma. Furthermore, the ongoing commitment to advancing pivotal Phase 2 clinical trials for multiple cancer indications positions IO Biotech favorably within the competitive biopharmaceutical landscape, particularly with encouraging efficacy data and a focus on critical patient subgroups.

The negative outlook on IO Biotech's stock is primarily driven by a significant shift from anticipated near-term regulatory review to the necessity of planning a new, large pivotal trial, resulting in a reduced valuation and price target. Additionally, the probability of success (POS) for key product candidates has seen substantial reductions, particularly for 1L melanoma from 50% to 30%, and for 1L head and neck (H&N) and non-small cell lung cancer (NSCLC) from 10% to 5%. Furthermore, the company faces various operational risks, including the need for approximately $400 million in additional financing, clinical safety and efficacy concerns, and potential de-listing if shares fall below $1, which collectively undermine investor confidence.